252 related articles for article (PubMed ID: 35958609)
1. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
Front Immunol; 2022; 13():894410. PubMed ID: 35958609
[TBL] [Abstract][Full Text] [Related]
2. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
3. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
Hou FQ; Song LW; Yuan Q; Fang LL; Ge SX; Zhang J; Sheng JF; Xie DY; Shang J; Wu SH; Sun YT; Wei SF; Wang MR; Wan MB; Jia JD; Luo GH; Tang H; Li SC; Niu JQ; Zhou WD; Sun L; Xia NS; Wang GQ
Theranostics; 2015; 5(3):218-26. PubMed ID: 25553110
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
Jia R; Wang WX; Zhou ZP; Nie WM; Cheng YQ; Zhao J; Lian F; Luan JQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1290-1296. PubMed ID: 38253073
[No Abstract] [Full Text] [Related]
5. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients.
Li MR; Zheng HW; Ma SM; Liu YY; Qie LX; Li JQ; Wang DH; Sun XL; Ren GF; Zheng YH; Wang YL; Dai EH
J Chin Med Assoc; 2018 Dec; 81(12):1052-1059. PubMed ID: 30143430
[TBL] [Abstract][Full Text] [Related]
6. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
Liang H; Wang C; Zhu PF; Zeng QL; Huang XB; Pan YF; Pan YJ; Hu QY; Luo X; Chen H; Yu ZJ; Lu FM; Lyu J
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1297-1305. PubMed ID: 38253074
[No Abstract] [Full Text] [Related]
7. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
8. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
9. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
[No Abstract] [Full Text] [Related]
10. [Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance].
Lin X; Wang XX; Song AX; Lu JF; Liu YL; Jin Y; Cao ZH; Ma LN; Zheng YY; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):673-678. PubMed ID: 34371538
[No Abstract] [Full Text] [Related]
11. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
[TBL] [Abstract][Full Text] [Related]
12. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
[TBL] [Abstract][Full Text] [Related]
13. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of qAnti-HBc with antiviral efficacy in children with chronic hepatitis B and exploration of its possible immune mechanism].
Zhou YZ; Chang YN; He Y; Wang HM; Peng XR; Chen M; Peng ML; Hu P; Ren H; Xu HM
Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):837-843. PubMed ID: 34638201
[No Abstract] [Full Text] [Related]
15. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
[TBL] [Abstract][Full Text] [Related]
16. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
Dezanet LNC; Maylin S; Gabassi A; Rougier H; Miailhes P; Lascoux-Combe C; Chas J; Girard PM; Delaugerre C; Lacombe K; Boyd A
J Infect Dis; 2020 May; 221(11):1826-1837. PubMed ID: 31960918
[TBL] [Abstract][Full Text] [Related]
19. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
20. Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
Wang X; Gao X; Wu R; Chi X; Xu H; Guan Y; Jin Q; Niu J
J Gastroenterol Hepatol; 2022 Sep; 37(9):1806-1814. PubMed ID: 35509262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
